Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H11N5O |
Molar mass | 301.309 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ocinaplon is an anxiolytic drug in the pyrazolopyrimidine family of drugs. Other pyrazolopyrimidine drugs include zaleplon and indiplon.
Ocinaplon has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and relatively little sedative or amnestic effect. [1]
A 2019 review found tentative evidence of benefit in anxiety. [2]
The mechanism of action by which ocinaplon produces its anxiolytic effects is by modulating GABAA receptors, [3] although ocinaplon is more subtype-selective than most benzodiazepines. [4]
Development of ocinaplon is discontinued due to liver complications that occurred in one of the Phase III subjects. [5]
Condensation of 4-Acetylpyridine [8] with N,N-Dimethylformamide dimethyl acetal ( DMFDMA) gives the "enamide" (3). This is then condensed with (3-Amino-1H-pyrazol-4-yl)(2-pyridinyl)methanone (4) (96219-90-8). [9] [10] This is the same intermediate as was used in the synthesis of zaleplon in which the nitrile is replaced by a 2-acetylpyridil moiety. This affords the anxiolytic agent ocinaplon (5).
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H11N5O |
Molar mass | 301.309 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Ocinaplon is an anxiolytic drug in the pyrazolopyrimidine family of drugs. Other pyrazolopyrimidine drugs include zaleplon and indiplon.
Ocinaplon has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and relatively little sedative or amnestic effect. [1]
A 2019 review found tentative evidence of benefit in anxiety. [2]
The mechanism of action by which ocinaplon produces its anxiolytic effects is by modulating GABAA receptors, [3] although ocinaplon is more subtype-selective than most benzodiazepines. [4]
Development of ocinaplon is discontinued due to liver complications that occurred in one of the Phase III subjects. [5]
Condensation of 4-Acetylpyridine [8] with N,N-Dimethylformamide dimethyl acetal ( DMFDMA) gives the "enamide" (3). This is then condensed with (3-Amino-1H-pyrazol-4-yl)(2-pyridinyl)methanone (4) (96219-90-8). [9] [10] This is the same intermediate as was used in the synthesis of zaleplon in which the nitrile is replaced by a 2-acetylpyridil moiety. This affords the anxiolytic agent ocinaplon (5).